Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides.
Two E. coli expressed recombinant polypeptides (rPvMSP-114 and rPvMSP-120) contained in the 33 kDa fragment, located within Plasmodium vivax merozoite surface protein (PvMSP-1) 42 kDa C-terminal region, and a cocktail of high reticulocyte binding synthetic peptides located within these fragments, we...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2003
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/26991
- Acceso en línea:
- https://doi.org/10.1016/S0264-410X(03)00455-9
https://repository.urosario.edu.co/handle/10336/26991
- Palabra clave:
- Plasmodium vivax
MSP-1
Immunisation
33 kDa fragment
Heterologous challenge
- Rights
- License
- Restringido (Acceso a grupos específicos)
id |
EDOCUR2_498f006990994535253a66ebd0f44012 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/26991 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
bc790c1a-5555-40ba-8c5f-98ea85a9518f-18d1788a6-8d70-4475-ab63-5af1c6ad7a3c-1faaf745c-61cf-4170-a36f-07c6154b327c-1781f6bf5-84f1-4537-afd1-59bc933d682f-1c7b5067d-0805-42bd-ba53-04d4f30d5dd8-151721018-1796530656002020-08-19T14:40:42Z2020-08-19T14:40:42Z2003Two E. coli expressed recombinant polypeptides (rPvMSP-114 and rPvMSP-120) contained in the 33 kDa fragment, located within Plasmodium vivax merozoite surface protein (PvMSP-1) 42 kDa C-terminal region, and a cocktail of high reticulocyte binding synthetic peptides located within these fragments, were evaluated for immunogenicity and protective immune responses in splenectomised and spleen intact Aotus nancymaae monkeys. Thirty splenectomised monkeys who had been previously immunised with either rPvMSP-114, rPvMSP-120, or a mixture of both recombinant fragments were intravenously challenged with the heterologous P. vivax VCG-1 strain (as determined by DNA sequencing); full protection was observed in five monkeys and low parasitaemia levels were obtained in eight more monkeys. Splenectomised control monkey group rapidly developed high parasitaemia levels, while no significant parasitaemia was obtained in the non-splenectomised control group. Although PvMSP-1 42 and 33 kDa fragments were recognised by Western Blot and whole parasites by IFAT when tested with immune monkey sera, no correlation between protection and antibody titres by IFAT and ELISA was observed, suggesting that protection is not being solely mediated by a humoral immune response. This data showed that partial protection against a heterologous strain challenge was best achieved when immunising with a rPvMSP-114–rPvMSP-120 mixture (2 were fully protected and 4 with low parasitaemia out of 12) suggesting for the first time, that these fragments could be good candidates for inclusion in a P. vivax multi-stage, multi-antigen vaccine.application/pdfhttps://doi.org/10.1016/S0264-410X(03)00455-9ISSN: 0264-410XEISSN: 1873-2518https://repository.urosario.edu.co/handle/10336/26991engElsevier4144No. 27-304133VaccineVol. 21Vaccine, ISSN: 0264-410X ;EISSN: 1873-2518 , Vol.21, No.27-30 (1 Octubre de 2003); pp. 4133-4144https://www.sciencedirect.com/science/article/pii/S0264410X03004559?via%3DihubRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecVaccineinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURPlasmodium vivaxMSP-1Immunisation33 kDa fragmentHeterologous challengeSplenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides.Respuesta inmune de los monos Aotus esplenectomizados y con el bazo intacto a los fragmentos de proteína Plasmodium vivax MSP-1 y sus péptidos de unión de alta actividad.articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Sierra, Adriana YanettBarrero, Carlos ALbertoRodriguez, RaulSilva, YolandaMoncada, CamiloVanegas, MagnoliaPatarroyo, Manuel A.10336/26991oai:repository.urosario.edu.co:10336/269912022-05-02 07:37:13.502449https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
dc.title.TranslatedTitle.spa.fl_str_mv |
Respuesta inmune de los monos Aotus esplenectomizados y con el bazo intacto a los fragmentos de proteína Plasmodium vivax MSP-1 y sus péptidos de unión de alta actividad. |
title |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
spellingShingle |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Plasmodium vivax MSP-1 Immunisation 33 kDa fragment Heterologous challenge |
title_short |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
title_full |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
title_fullStr |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
title_full_unstemmed |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
title_sort |
Splenectomised and spleen intact Aotus monkeys'immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. |
dc.subject.keyword.spa.fl_str_mv |
Plasmodium vivax MSP-1 Immunisation 33 kDa fragment Heterologous challenge |
topic |
Plasmodium vivax MSP-1 Immunisation 33 kDa fragment Heterologous challenge |
description |
Two E. coli expressed recombinant polypeptides (rPvMSP-114 and rPvMSP-120) contained in the 33 kDa fragment, located within Plasmodium vivax merozoite surface protein (PvMSP-1) 42 kDa C-terminal region, and a cocktail of high reticulocyte binding synthetic peptides located within these fragments, were evaluated for immunogenicity and protective immune responses in splenectomised and spleen intact Aotus nancymaae monkeys. Thirty splenectomised monkeys who had been previously immunised with either rPvMSP-114, rPvMSP-120, or a mixture of both recombinant fragments were intravenously challenged with the heterologous P. vivax VCG-1 strain (as determined by DNA sequencing); full protection was observed in five monkeys and low parasitaemia levels were obtained in eight more monkeys. Splenectomised control monkey group rapidly developed high parasitaemia levels, while no significant parasitaemia was obtained in the non-splenectomised control group. Although PvMSP-1 42 and 33 kDa fragments were recognised by Western Blot and whole parasites by IFAT when tested with immune monkey sera, no correlation between protection and antibody titres by IFAT and ELISA was observed, suggesting that protection is not being solely mediated by a humoral immune response. This data showed that partial protection against a heterologous strain challenge was best achieved when immunising with a rPvMSP-114–rPvMSP-120 mixture (2 were fully protected and 4 with low parasitaemia out of 12) suggesting for the first time, that these fragments could be good candidates for inclusion in a P. vivax multi-stage, multi-antigen vaccine. |
publishDate |
2003 |
dc.date.created.spa.fl_str_mv |
2003 |
dc.date.accessioned.none.fl_str_mv |
2020-08-19T14:40:42Z |
dc.date.available.none.fl_str_mv |
2020-08-19T14:40:42Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/S0264-410X(03)00455-9 |
dc.identifier.issn.none.fl_str_mv |
ISSN: 0264-410X EISSN: 1873-2518 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/26991 |
url |
https://doi.org/10.1016/S0264-410X(03)00455-9 https://repository.urosario.edu.co/handle/10336/26991 |
identifier_str_mv |
ISSN: 0264-410X EISSN: 1873-2518 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
4144 |
dc.relation.citationIssue.none.fl_str_mv |
No. 27-30 |
dc.relation.citationStartPage.none.fl_str_mv |
4133 |
dc.relation.citationTitle.none.fl_str_mv |
Vaccine |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 21 |
dc.relation.ispartof.spa.fl_str_mv |
Vaccine, ISSN: 0264-410X ;EISSN: 1873-2518 , Vol.21, No.27-30 (1 Octubre de 2003); pp. 4133-4144 |
dc.relation.uri.spa.fl_str_mv |
https://www.sciencedirect.com/science/article/pii/S0264410X03004559?via%3Dihub |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_16ec |
dc.rights.acceso.spa.fl_str_mv |
Restringido (Acceso a grupos específicos) |
rights_invalid_str_mv |
Restringido (Acceso a grupos específicos) http://purl.org/coar/access_right/c_16ec |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier |
dc.source.spa.fl_str_mv |
Vaccine |
institution |
Universidad del Rosario |
dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167430139740160 |